Introduction
Vitamin D has long been known as an important factor in bone health. Multiple studies over the past two decades have shown that beyond its critical role in bone physiology, calciferols are implicated in the pathogenesis of disorders with neoplastic, inflammatory or infectious origin by modulation of the biological activities of the corresponding genes (Holick, 2004; Bikle, 2009) .
Vitamin D deficiency is a major health problem and studies conducted during the past decade have shown reoccurrence of the problem in many countries around the world irrespective of their economic, cultural or geographic diversity (Holick, 2007; Kimball et al., 2008) . The Middle East, the land of every day sun, is by no means an exception. Studies conducted in Iran and neighboring countries clearly demonstrate severe vitamin D deficiency in different age groups, especially in women, most probably because of the type of clothing and deficient oral intake of vitamin D, which is 50-110 U per day (Sedrani et al., 1983; Alagol et al., 2000; Hashemipour et al., 2004; Mirsaeid Ghazi et al., 2004; Ainy et al., 2006; Dahifar et al., 2007; Baroncelli et al., 2008) . Mean daily intake of calcium (Ca) is 580-600 mg (Du et al., 2001; El-Hajj Fuleihan et al., 2001) , hence the people in the region have mixed Ca and vitamin D deficiency.
Hypovitaminosis D is highly prevalent in adolescents (Lehtonen-Veromaa et al., 1999; Du et al., 2001; Mark et al., 2008; Sahu et al., 2009) ; limited data on adolescents residing in rural areas demonstrate same problem on an even greater scale (Cheng et al., 2003) . In almost all studies, vitamin D deficiency has been shown to be more prominent in girls, even exaggerated during winter. Some studies have demonstrated lower bone mineral density and greater bone loss during winter, both important negative factors in gaining optimum height and accrual of maximum bone mass (Cashman et al., 2008) . Although most studies have reached to similar conclusions regarding the prevalence of vitamin D deficiency and the need for urgent therapeutic modalities and increases in the daily recommendations of vitamin D supplementation, there is no consensus regarding optimum vitamin D supplementation and publication of multiple randomized control trials has not been able to convince the authorities to change the recommended daily dose of vitamin D (Vieth et al., 2007) .
This study was designed to demonstrate the effects of different doses of oral cholecalciferol in a group of schoolchildren living in a mountainous area, where long-lasting winter, prolonged deprivation from sun exposure and lack of food exchange can potentiate borderline vitamin D deficiency. The study was conducted in Taleghan, a mountainous area, 140 km northwest of Tehran, the capital city of Iran, latitude of 36.51N and an altitude of 1850 m above sea level.
Subjects and methods

Study protocol and design
The study was a randomized, double-blind, parallel, placebocontrolled trial. In total, 210 schoolchildren, aged 14-20 years, were recruited. All the subjects were active students (105 boys, 105 girls) without any chronic disease affecting bone metabolism. Exclusion criteria included taking any kind of vitamin D or Ca supplements or any drugs known to interfere with bone metabolism, before and during the study. After subject enrollment, they were randomly assigned to three groups, A, B and C, using computer-generated random number table. Each group contained 35 boys and 35 girls. Randomization was performed with the use of sealed envelopes. Group A was assigned to receive 50 000 U oral vitamin D 3 or cholecalciferol (manufactured by Roche Pharmaceutical, Tehran, Iran and dispersed in Iran by Zahravi, Tehran, Iran) monthly, group B, the same amount every 2 months and a similar shaped placebo every alternative month. Group C was assigned to take just the placebo monthly. Neither the research team nor the subjects was informed about type of intervention in the study. A written consent was obtained from each participant and they were free to leave study whenever they wanted. The study protocol was approved by the research ethics committee of the Research Institute for Endocrine Sciences, affiliated to Shahid Beheshti University of Medical Sciences.
The study began in November 2007 and was completed in April 2008. At the first session, students were examined by the research team and baseline information, anthropometric measurements and first blood and urine samples were obtained. The students were asked to take vitamin D 3 or the placebo in front of the research team. The research team met at the scene every month, examined the students and administered the medicine or placebo personally, throughout the research period.
Blood sampling and measurements Venous blood (5 ml) and fresh urine sample were taken from each student. Second and third samplings were performed in January and April 2008, respectively. Blood and urine samples were transferred to the laboratory of Research Institute for Endocrine Sciences, centrifuged and kept at À80 1C. All the samples were evaluated in one run at the end of study.
Intact parathyroid hormone (iPTH), 25(OH)D, bonespecific alkaline phosphatase (BSALP) and osteocalcin (OC) were measured by the ELISA kits (Immunodiagnostic Systems, Boldon, UK). The assay sensitivities for BSALP, OC, PTH and 25(OH)D were 0.7 mg/l, 0.5 ng/ml (0.08 nmol/l), 0.06 pmol/l and 5 nmol/l, respectively. All the intra-and interassay coefficient of variations were o10%.
Serum albumin, Ca and creatinine and urine Ca and creatinine were measured by colorimetric kits (Pars Azmoun, Tehran, Iran), the assay being run through an instrumental autoanalyzer (Selectra II; Dieren, The Netherlands). All the intra-and interassay coefficients of variation for the biochemical analytes were o4%.
Urine C-telopeptide level was measured by the ELISA kit (Immunodiagnostic Systems). The assay's intra-and intercoefficient of variations were o10%. The assay sensitivity was 50 mg/l.
Statistical analysis
Data were summarized as mean (±s.d.) and categorical variables were expressed as percentage. Logarithmic transformation was performed to normalize the distribution of PTH. Differences of continuous variables between the three groups were analyzed, using analysis of variance with the Tukey's post hoc test. Repeated-measure analyses of variance were performed to test whether time trends differ between the three treatment groups and whether there is a time effect within each treatment group. Analyses were carried out using SPSS software version 15.0 (SPSS, Chicago, IL, USA). Po0.05 was considered statistically significant.
Results
Baseline characteristics of the subjects Of the original 210 enrollees, 207 completed the study; 2 were excluded because of consumption of supplements during study and 1 left the study. Mean age of the study population was 16.3±1.3 years and they had a mean body mass index of 21±3.6. Anthropometric and biochemical variables were similar among treatment groups (Table 1) . Baseline 25(OH)D mean levels were 32±22, 28.25±14.5, 29±18 and 29.75±18.5 nmol/l in groups A, B, C and total, respectively. In total, 78% of the subjects had 25(OH)D levels o50 nmol/l. Mean 25(OH)D levels of the girls in all three groups were about half the values in boys. Percentages of the boys and girls with 25(OH)D levels o50 nmol/l were 77 (79 out of 103) and 97 (101 out of 104), respectively.
Baseline geometric mean and 95% confidence interval of iPTH were 2.23 and 2.01-2.35 pmol/l, respectively. On the basis of the normal values of the iPTH (0.76-3.7 pmol/l), we diagnosed 6.8% of the boys and 15.4% of the girls as secondary hyperparathyroidism; in total, 18.4% of boys and 21.2% of girls had serum Ca o2.15 mmol/l (kit's lower limit) and urine Ca/creatinine ratio was o0.08 in 54.9% of boys and 45% of girls. Mean values of baseline OC and BSALP were lower in girls in comparison with the boys. Considering the marked differences in the biochemical variables of male and female participants, we analyzed the data in boys and girls separately.
Boys
Repeated-measure ANOVA revealed significant effects of treatment and time (Po0.001) for serum 25(OH)D, iPTH and Ca (Figure 1 ). Mean 25(OH)D in group A increased from 43.75 ± 14 at baseline to 72.5 ± 26.25 nmol/l at the end of study (Po0.001), the increment of 25(OH)D being greater in group A than in group B (Po0.001). In group B, it increased from 39 ± 12 to 57.75 ± 19 nmol/l. In the placebo group, there was no significant difference in 25(OH)D levels during the study period. At the end of study, 15.6% of participants in group A, 35.5% of group B and 76% of group C had a mean 25(OH)D level o50 nmol/l.
PTH dropped significantly at the end of the study in groups A and B (Po0.001).Although all the subjects in groups A and B had normal serum PTH, secondary hyperparathyroidism was observed in 7% of subjects in group C. No case of hypocalcemia was observed in boys.
BSALP did not change among treatment groups, but OC increased slightly at the end of study (Po0.05). Urine C telopeptide levels dropped during the study in groups A and B (Po0.01), but there were no significant differences in mean urine Ca/creatinine ratio levels between all the groups during the study (Table 2) .
Girls
Repeated-measures ANOVA revealed significant effects of treatment and time (Po0.001) for serum 25(OH)D, iPTH and Ca (Figure 1 ). Mean serum 25(OH)D levels increased from 20.5±22.5 and 17.5±6 nmol/l at the beginning of the study to 48±23.5 and 33.75±23 nmol/l during the 5-month treatment in groups A and B, respectively (Po0.001). At the end of the study, mean serum 25(OH)D level was higher in group A in comparison with group B, whereas no significant difference could be found in the placebo group. Although the treated subjects showed improvement in their vitamin D status, 63.6% of the girls in group A and 74.2% in group B had 25(OH)D levels o50 nmol/l.
PTH dropped significantly at the end of the study in group A and B (Po0.001). Secondary hyperparathyroidism was observed in 6.1% of group A, 6.5% of group B and 15.2% of group C. At the end of study, serum Ca levels below 2.15 mmol/l were observed in 9.1% of girls in group C. OC increased significantly in treatment groups, whereas BSALP increased only in group A (Po0.001). Urine Ca/creatinine ratio and urine C telopeptide did not change significantly during the study (Table 3 ).
Discussion
The study shows that in high-school adolescents residing in a mountainous area (latitude 36. 51), with high prevalence of vitamin D deficiency, 50 000 IU oral vitamin D 3 , monthly or bimonthly, during fall and winter was well tolerated and significantly increased serum 25(OH)D levels.
The intervention also significantly increased serum Ca and decreased serum PTH concentrations. However, because of severity of the problem and long-lasting nature of hypovitaminosis D, a considerable fraction of subjects were still vitamin D deficient at the end of winter (Figure 2) . In other words, whereas mean serum 25(OH)D level in all subjects increased from 29.75 ± 18.5 to 45.25 ± 26.75 nmol/l, 40% of students at the end of the study had 25(OH)D levels below 50 nmol/l. Vitamin D deficiency was more pronounced in girls, in comparison with boys, hence lower percentage of girls reached 25(OH)D levels above 50 nmol/l with the same doses of vitamin D (63 vs 16%). Regarding safety profiles, no case of vitamin D intoxication or hypercalcemia was observed.
During the past two decades, medical literature has been flooded with articles addressing biological significance of vitamin D and also reemergence of deficiency states of cholecalciferol on a worldwide scale. According to the data provided, 30-70% of people from different communities have varying degrees of hypovitaminosis D (Sedrani, 1984; El-Hajj Fuleihan et al., 2001; Nesby-O'Dell et al., 2002; Gordon et al., 2004; Vieth, 2004; Sullivan et al., 2005; Bodnar et al., 2007) .
On the basis of these findings, it is evident that new strategies need to be implemented to improve the status of Figure 1 Changes in mean ± s.e. levels of 25(OH)D, PTH and Ca in group A (50 000 U cholecalciferol monthly), group B (50 000 U cholecalciferol bimonthly) and group C (placebo) during the study period.
Vit D 3 supplementation in schoolchildren AA Ghazi et al body cholecalciferol (Prentice, 2008; Ginde et al., 2009; Holick, 2009; Orwoll et al., 2009 With lower values, a tendency to hypocalcemia develops that is followed by secondary hyperparathyroidism, increased osteoclastic activity and increased bone resorption that finally terminates to decreased bone density. This sequence of events is especially harmful for people of pediatric and adolescent age, in whom the majority of bone mass accrual occurs during this critical period of life (Aksnes and Aarskog, 1982; Ilich et al., 1997) . Abbreviations: BSALP, bone-specific alkaline phosphatase; Ca, calcium; Cr, creatinine; PTH, parathyroid hormone. * Po0.001, ** Po0.05 paired t-test between 0 and 5 months. There are a few studies in which different doses of vitamin D have been used to achieve the desired level of 25(OH)D and prevent the natural winter drop of body vitamin D pool in adolescents and young adults. Lehtonen-Veromaa et al. (1999) have shown that in prepubertal Finnish girls, the daily supplementation of 400 U of vitamin D 2 during fall and winter was insufficient to raise 25(OH)D level from baseline. In spite of significant increment of 25(OH)D after the daily supplementation of 800 U of vitamin D 2 , the mean level of 25(OH)D was still below 50 nmol/l (Lehtonen-Veromaa et al., 1999) . In French male adolescents, oral administration of 100 000 U vitamin D 3 , repeated every 2 months for 6 months, led to same level of 25(OH)D at the end of winter in comparison with September, but in untreated subjects a significant decrease was observed toward March (Guillemant et al., 2001) . Maalouf et al. (2008) evaluated the effect of weekly 1400 and 14 000 U of vitamin D 3 in both sexes for 1 year; mean 25(OH)D in subjects receiving 14 000 U per week, increased from 37.5 ± 17.5 to 90 ± 55 nmol/l. It is important to note that no case of vitamin D intoxication was observed in this study, demonstrating that doses equivalent to 2000 U per day are safe in adolescents. Studies conducted by Zeghoud et al. (1995) , Oliveri et al. (1996) and Tau et al. (2007) from France and Argentina with administration of 100 000 U vitamin D 3 single dose, 150 000 U vitamin D 2 single dose and 100 000 U vitamin D 3 , every 3 months, respectively, during fall and winter revealed that treated groups had higher levels of 25(OH)D in comparison with untreated groups. In our study, hypovitaminosis D was more pronounced in girls in comparison with boys, and the values in both sexes were lower than those reported from other countries, such as Lebanon, Argentina and the United States, indicating that the problem has greater dimensions in our country and Iranian females have the deficiency to a greater extent, partly because of the type of covered Islamic clothing that is worn today. According to our study, although supplementation could increase serum 25(OH)D significantly, only limited number of the subjects reached the level of 50 nmol/l. It may be because of the severe and long-standing deficiency, especially in girls and the need for supplementation with either higher doses or longer periods to replenish body stores.
Significant reduction in serum PTH in groups A and B indicates that vitamin D supplementation even with suboptimal amounts could have been effective to prevent this untoward compensatory response during fall and winter. The increase in serum Ca in groups A and B is also attributed to the supplementation and highlights the fact that increasing body cholecalciferol pool, improves the body Ca status, even when the Ca intake has not been increased. Regarding urine Ca excretion, our impression is that the plateau status of this variable may be because of low body Ca pool, low dietary calcium intake and low vitamin D levels of the participants. Increase in urine Ca excretion may be the final step in improvement of body Ca pool and can be expected when vitamin D is advised with higher doses or for longer periods in conjunction with oral Ca supplements.
An unexpected finding was the lower baseline levels of OC in girls and the increment of the substance in both sexes after different doses of vitamin D 3 . Lower levels of OC in girls can be explained by lower levels of 25(OH)D and the findings are in agreement with the data provided by Baroncelli et al. (2000) , who demonstrated osteoblastic hypofunction and lower levels of OC due to severe vitamin D deficiency. Accordingly, we can hypothesize that in context of severe long-standing vitamin D deficiency, pattern of bone formation response to treatment may be different at least in early months. It is possible to detect expected OC decreasing trend in an extended follow-up.
Several limitations of our study deserve comment. First, we could not evaluate daily intake of vitamin D and Ca in our study population; our observations, however, revealed that there had been no difference in the dietary patterns of participants during the study period. Second, it would have been better to do the first sampling just at the end of summer, but because of time coinciding with Ramadhan, the month of Islamic fasting, we could do the first sampling in November. Third, although we could not evaluate the pubertal stage of the participants because of their cultural and religious beliefs, age and menstrual history revealed that all of them had completed the puberty. Fourth, as the sample size was calculated for 25(OH)D, the power was not enough to detect bone marker changes. Finally, because of reluctance of the participants to collect urine for 24 h, we relied on morning urine sample and adjusted the results with urine creatinine to enhance accuracy.
In conclusion, our study clearly shows that in schoolchildren of underserved mountainous areas, with high prevalence of vitamin D deficiency, monthly or bimonthly administration of 50 000 U vitamin D 3 , during fall and winter improves the status of body vitamin D, although it may not be able to ensure the desired levels of serum 25(OH)D. Optimum 25(OH)D level, that is, 75 nmol/l may be achieved with either higher doses or longer period of supplementation. Improved levels of serum 25(OH)D, PTH and serum Ca following supplementation undoubtedly ensure having bones with better quality.
